Energy News / Shareholders Foundation, Inc.

NASDAQ:OHRP Shareholder Notice: Investigation of Potential Wrongdoing at OHR Pharmaceutical Inc

Via: ReleaseWire

Updated 12:00 PM CDT, Tue, June 19,2018

An investigation on behalf of current long term investors in OHR Pharmaceutical Inc (NASDAQ:OHRP) shares over possible breaches of fiduciary duty by certain officers and directors was announced.

San Diego, CA -- (SBWIRE) -- 06/19/2018 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of OHR Pharmaceutical Inc (NASDAQ:OHRP was announced.

Investors who are investors in OHR Pharmaceutical Inc (NASDAQ:OHRP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for investors in NASDAQ:OHRP stocks follows a lawsuit filed against OHR Pharmaceutical over alleged securities laws violations. The investigation on behalf of investors in NASDAQ:OHRP stocks, concerns whether certain OHR Pharmaceutical directors are liable in connection with the allegations made in that lawsuit.

The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that OHR Pharmaceutical Inc's lead product Squalamine would not produce vision improvements and was commercially not viable, and that as a result of the foregoing, Defendants' statements about OHR Pharmaceutical Inc's business, operations, and prospects were misleading and/or lacked a reasonable basis.

Those who purchased shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqohrp-shareholder-notice-investigation-of-potential-wrongdoing-at-ohr-pharmaceutical-inc-996967.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com